Diabetes & Metabolism Journal

Guoyue Yuan

1 Article

Metabolic Risk/Epidemiology
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism: Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan; Diabetes Metab J. 2024;48(3):354-372. Published online April 1, 2024; DOI: https://doi.org/10.4093/dmj.2023.0277

35,114 View
1,237 Download
21 Web of Science
24 Crossref

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning. GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism. It is expected to become a new target for the treatment of metabolic disorders. The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases. This article reviews the recent research progress of GLP-1 in lipid metabolism.

Citations

Citations to this article as recorded by

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
Jae Hyun Bae, Young Min Cho
Journal of Diabetes Investigation.2025; 16(2): 183. CrossRef
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Kathryn L. Williams, Maya Augustine, Eru Sujakhu, Justine Magadia, Lindsay Crawford, Aimee Knott, Skyler Hamilton, Uzoma Obiaka
Progress in Pediatric Cardiology.2025; 76: 101775. CrossRef
The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy
Chien-Yin Kuo, Sing-Hua Tsou, Edy Kornelius, Kuei-Chuan Chan, Kai-Wei Chang, Jung-Chi Li, Chien-Ning Huang, Chih-Li Lin
Cellular and Molecular Life Sciences.2025;[Epub] CrossRef
An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits
Laxman Subedi, Arjun Dhwoj Bamjan, Susmita Phuyal, Jung-Hyun Shim, Seung-Sik Cho, Jong Bae Seo, Kwan-Young Chang, Youngro Byun, Seho Kweon, Jin Woo Park
Journal of Controlled Release.2025; 378: 637. CrossRef
Engineering a high‐throughput clone for industrial‐scale production of long‐acting GLP‐1 analogue with retained bio‐efficacy
Praveen Kumar Reddy J, Murali Tummuru, Kunka Mohanram Ramkumar
Biotechnology Progress.2025;[Epub] CrossRef
Role of molecular hydrogen in obesity treatment: modulation of GLP-1, irisin, and PGC-1α for improved metabolism
Nikola Todorović, Jovan Kuzmanovic, Dejan Javorac, Sergej M. Ostojic
Medical Gas Research.2025; 15(3): 442. CrossRef
Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis
Long He, Jinwei Li, Xiong Cheng, Li Luo, Yilan Huang
Frontiers in Pharmacology.2025;[Epub] CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot
Eda Kaya, Wing-Kin Syn, Paul Manka
Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide
Mun-Teng Wong, Pei-Hsuan Lin, Wei-Chen Lin, Chi-Jiun Peng, Jon D. Wright, Hui-Ju Lee, Hsing-Mao Chu, Carmay Lim, Tse Wen Chang
Journal of Medicinal Chemistry.2025; 68(6): 6178. CrossRef
Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
Ashley Wang, Savannah Bitzas, Dilsa Perez, Jonathon Schwartz, Saleem Zaidi, Jonathan Oster, Sergio D. Bergese
Life.2025; 15(3): 427. CrossRef
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Blair Suter, Allison Rhodes, Allison Bigeh, Timothy Frommeyer, Laxmi S. Mehta
Current Cardiovascular Risk Reports.2025;[Epub] CrossRef
The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases
Eliane Münte, Phillipp Hartmann
Biomolecules.2025; 15(4): 469. CrossRef
Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice
Caroline de Carvalho Picoli, Sergey Tsibulnikov, Mavy Ho, Victoria DeMambro, Tiange Feng, May Eltahir, Phuong T. Le, Carolyn Chlebek, Clifford J. Rosen, Sergey Ryzhov, Ziru Li
American Journal of Physiology-Endocrinology and Metabolism.2025; 328(4): E555. CrossRef
Pre-fertilization-origin preservation of brown fat-mediated energy expenditure in humans
Takeshi Yoneshiro, Mami Matsushita, Sayuri Fuse-Hamaoka, Miyuki Kuroiwa, Yuko Kurosawa, Yosuke Yamada, Makoto Arai, Yuchen Wei, Makoto Iida, Kenichi Kuma, Toshimitsu Kameya, Tomoya Harada, Yoshihiro Matsumura, Tsuyoshi Osawa, Yoshiko Aoki, Hisashi Nakamur
Nature Metabolism.2025;[Epub] CrossRef
Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study
Wenxuan Li, Yangang Wang, Chuanfeng Liu, Yongzhuo Yu, Lili Xu, Bingzi Dong
Diabetes Therapy.2025; 16(5): 993. CrossRef
Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells
Sing-Hua Tsou, Kai-Shin Luo, Chien-Ning Huang, Edy Kornelius, I-Ting Cheng, Hui-Chih Hung, Yu-Chien Hung, Chih-Li Lin, Min-Yen Hsu
International Journal of Molecular Sciences.2025; 26(8): 3704. CrossRef
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi
Biomedicines.2024; 12(8): 1630. CrossRef
The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
Vincenzo Rochira, Carla Greco, Stefano Boni, Francesco Costantino, Leonardo Dalla Valentina, Eleonora Zanni, Leila Itani, Marwan El Ghoch
Diseases.2024; 12(9): 204. CrossRef
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders
John O Olukorode, Dolapo A Orimoloye, Nwachukwu O Nwachukwu, Chidera N Onwuzo, Praise O Oloyede, Temiloluwa Fayemi, Oluwatobi S Odunaike, Petra S Ayobami-Ojo, Nwachi Divine, Demilade J Alo, Chukwurah U Alex
Cureus.2024;[Epub] CrossRef
Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Jorge F.A. Model, Rafaella S. Normann, Éverton L. Vogt, Maiza Von Dentz, Marjoriane de Amaral, Rui Xu, Tsvetan Bachvaroff, Poli Mara Spritzer, J. Sook Chung, Anapaula S. Vinagre
Biochemical Pharmacology.2024; 230: 116623. CrossRef
Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies
Karen Feghali, Xilong Li, Naim M. Maalouf
Kidney360.2024; 5(11): 1706. CrossRef
Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway
Mingyun Tang, Long Zhao, Fuchun Huang, Tiangang Wang, Xu Wu, Shanshan Chen, Juan Fu, Chaoli Jiang, Shulin Wei, Xuseng Zeng, Xiaoling Zhang, Xin Zhou, Mei Wei, Zhi Li, Guohui Xiao
Frontiers in Nutrition.2024;[Epub] CrossRef
Spotlight on the Mechanism of Action of Semaglutide
Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi
Current Issues in Molecular Biology.2024; 46(12): 14514. CrossRef

Author index